These enzymes are upregulated by estrogen (ER) or androgen (AR) receptors, highlighting the importance of this pathway in hormone-receptor-positive cancers, such as ER+ breast and AR+ prostate cancers [132,133]. Here, PIEZO1 is linked to prostate cancer.